Feb 26, 2024
Dr. John Showalter, Chief Product Officer of Linus Health, shines a light on the current methods of measuring cognitive health and emphasizes the need for a more holistic approach to assessing brain health. Linus works on digital cognitive assessment tools and AI models to detect cognitive impairment and early warning...
Feb 26, 2024
Dr. John Showalter, Chief Product Officer of Linus Health, shines a light on the current methods of measuring cognitive health and emphasizes the need for a more holistic approach to assessing brain health. Linus works on digital cognitive assessment tools and AI models to detect cognitive impairment and early warning...
Feb 6, 2024
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals, is focused on developing next-generation therapies for neurological diseases, particularly schizophrenia. Their lead candidate, brilaroxazine, acts on multiple neuro receptors to balance imbalanced neurotransmitters in the brain that are...
Feb 6, 2024
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals, is focused on developing next-generation therapies for neurological diseases, particularly schizophrenia. Their lead candidate, brilaroxazine, acts on multiple neuro receptors to balance imbalanced neurotransmitters in the brain that are...
Dec 18, 2023
Jeffrey Madden, Co-Founder and CEO of ADvantage Therapeutics is developing therapies for neurodegenerative conditions, particularly Alzheimer's disease. Instead of pursuing the amyloid hypothesis, ADvantage is focused on neuroinflammation as the primary driver of Alzheimer's pathology. Trials for their lead compound...